{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:06:45Z","timestamp":1784203605261,"version":"3.55.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Advances in antiretroviral therapy (ART) have shifted the focus of HIV management towards metabolic comorbidities such as atherosclerotic cardiovascular disease (ASCVD). However, real-world data comparing lipid profile changes, key determinants of ASCVD, between bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) and dolutegravir\/lamivudine (DTG\/3TC) remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective cohort study was conducted using medical records from the National Medical Center, Seoul, South Korea, from January 2012 to March 2024. Lipid profiles were analysed over 2\u2005years following initiation of BIC\/FTC\/TAF or DTG\/3TC in treatment-na\u00efve people living with HIV (PLH). Individuals receiving lipid-lowering agents and a previous history of ASCVD were excluded. People with hepatitis B and\/or C virus infection were included, and infection status was adjusted for as a covariate along with alanine aminotransferase and aspartate aminotransferase. A linear mixed model was applied to compare lipid profiles between the different ART regimens over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 194 treatment-na\u00efve PLH were included in the final analysis: 137 (70.6%) initiated BIC\/FTC\/TAF and 57 (29.4%) initiated DTG\/3TC. Over 2\u2005years, longitudinal analysis showed that PLH receiving DTG\/3TC had significantly smaller LDL cholesterol increases over time compared to BIC\/FTC\/TAF (ART-by-time interaction: \u03b2\u200a=\u200a\u22128.03, P\u200a=\u200a0.035). The TC\/HDL-C ratio showed a trend towards improvement in the DTG\/3TC group (\u03b2\u200a=\u200a\u22120.19, P\u200a=\u200a0.094). Triglyceride levels remained stable with no significant ART-by-time interaction (\u03b2\u200a=\u200a17.60, P\u200a=\u200a0.271).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DTG\/3TC demonstrated more favourable lipid changes than BIC\/FTC\/TAF in treatment-na\u00efve individuals, with significantly smaller LDL cholesterol increases and a trend towards an improved TC\/HDL ratio over time. These findings may be informative during the ART selection especially for PLH with cardiovascular risk factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaf213","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:55:18Z","timestamp":1754063718000},"page":"2384-2390","source":"Crossref","is-referenced-by-count":3,"title":["Comparative analysis of lipid profile changes in treatment-na\u00efve people living with HIV on INSTI-based single-tablet regimens, BIC\/FTC\/TAF and DTG\/3TC: real-world evidence from South Korea"],"prefix":"10.1093","volume":"80","author":[{"given":"So Yun","family":"Lim","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, National Medical Center , Seoul, Republic of Korea"},{"name":"Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3021-1434","authenticated-orcid":false,"given":"BumSik","family":"Chin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, National Medical Center , Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, National Medical Center , Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, National Medical Center , Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonjae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, National Medical Center , Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2025090219520318400_dkaf213-B1","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"2025090219520318400_dkaf213-B2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2025090219520318400_dkaf213-B3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/QAD.0000000000002811","article-title":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents","volume":"35","author":"The RESPOND Study Group","year":"2021","journal-title":"AIDS"},{"key":"2025090219520318400_dkaf213-B4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2025090219520318400_dkaf213-B5","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"2025090219520318400_dkaf213-B6","doi-asserted-by":"publisher","first-page":"e26279","DOI":"10.1002\/jia2.26279","article-title":"Non-inferior efficacy and less weight gain when switching to DTG\/3TC than when switching to BIC\/FTC\/TAF in virologically suppressed people with HIV (PWH): the PASO-DOBLE (GeSIDA 11720) randomized clinical trial","volume":"27","author":"Ryan","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025090219520318400_dkaf213-B7","doi-asserted-by":"publisher","first-page":"ciae645","DOI":"10.1093\/cid\/ciae645","article-title":"Metabolic complications after initiating BIC\/FTC\/TAF versus DTG","author":"Garc\u00eda-Ruiz de Morales","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B8","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1093\/cid\/ciac621","article-title":"Metabolic-related outcomes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in adults with human immunodeficiency virus (HIV): a multicenter prospective cohort study","volume":"76","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B10","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B11","doi-asserted-by":"publisher","first-page":"ofad359","DOI":"10.1093\/ofid\/ofad359","article-title":"Cardiometabolic parameters 3 years after switch to dolutegravir\/lamivudine vs maintenance of tenofovir alafenamide-based regimens","volume":"10","author":"Batterham","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025090219520318400_dkaf213-B12","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"2025090219520318400_dkaf213-B13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"2025090219520318400_dkaf213-B14","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2025090219520318400_dkaf213-B15","first-page":"48","volume-title":"WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-Related Disease in Adults and Children","author":"World Health Organization","year":"2007"},{"key":"2025090219520318400_dkaf213-B16","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"2025090219520318400_dkaf213-B17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/14787210.2023.2279719","article-title":"Comparison of dolutegravir\u200a+\u200alamivudine and bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral therapy-na\u00efve patients infected with HIV: preliminary results from clinical practice","volume":"22","author":"Gan","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025090219520318400_dkaf213-B18","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001949","article-title":"Safety and efficacy of lamivudine\/dolutegravir vs. bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study","volume":"74","author":"Yang","year":"2025","journal-title":"J Med Microbiol"},{"key":"2025090219520318400_dkaf213-B19","author":"Rovito"},{"key":"2025090219520318400_dkaf213-B20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B21","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/cid\/ciae189","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV","volume":"79","author":"Damas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025090219520318400_dkaf213-B22","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2384\/63919949\/dkaf213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/9\/2384\/63919949\/dkaf213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T23:52:07Z","timestamp":1756857127000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/9\/2384\/8220906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,1]]},"published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf213","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,1]]}}}